Registry of the International Society for Heart and Lung Transplantation: Eighth Official Pediatric Report—2005

Age distribution of pediatric heart recipients (transplants: January 1996 to June 2004).

Age distribution of pediatric heart recipients by year of transplant.

Diagnosis in pediatric heart transplant recipients (age: <1 year).

Pediatric heart recipients’ maintenance immunosuppression at time of follow-up. Note: Different patients analyzed at Year 1 and Year 5 (follow-up: January 2000 to June 2004).

Pediatric heart recipients’ induction immunosuppression (follow-up: January 2001 to June 2004).

Percentage of pediatric heart transplant recipients treated for rejection in the first year stratified by maintenance immunosuppression and induction (transplants: January 2000 to June 2003).

Percentage of pediatric heart transplant recipients treated for rejection in the first year stratified by maintenance immunosuppression (transplants: January 2000 to June 2003).

Pediatric heart transplant Kaplan-Meier survival (1/1982 to 6/2003).

Pediatric heart transplant conditional Kaplan-Meier survival (1/1982 to 6/2003).

Pediatric heart transplant Kaplan-Meier survival stratified by tacrolimus vs cyclosporine use at discharge (transplants: January 1998 to June 2003) conditional on survival to 14 days.

Pediatric heart transplant (1/1995 to 6/2003) risk factors for 1-year mortality donor age.

Pediatric heart transplant Kaplan-Meier survival based on rejection within the first year (transplants: January 1998 to June 2002).

Pediatric heart transplant (1/1995 to 6/1999) risk factors for 5-year mortality conditional on 1-year survival recipient weight.

Pediatric heart transplant (1/1995 to 6/1999) risk factors for 5-year mortality conditional on 1-year survival ischemia time.

Freedom from coronary artery vasculopathy for pediatric heart recipients (follow-up: April 1994 to June 2004).

Freedom from coronary artery vasculopathy for pediatric heart recipients (follow-up: April 1994 to June 2004) stratified by induction.

Freedom from coronary artery vasculopathy for pediatric heart recipients (follow-up: April 1994 to June 2004) stratified by age group.

Graft survival after diagnosis of coronary artery vasculopathy for pediatric heart recipients (follow-up: April 1994 to June 2004) stratified by age group.

Pediatric heart recipient functional status of surviving recipients (follow-up: April 1994 to June 2004).

Pediatric heart transplant (1/1995 to 6/2003) 1-year predicted survival—hypothetical Cases 1 and 2.

Pediatric heart transplant (1/1995 to 6/2003) 1-year predicted survival—hypothetical Case 3.

Pediatric heart transplant (1/1995 to 6/2003) 1-year predicted survival—hypothetical Cases 4 and 5.

Pediatric heart transplant (1/1995 to 6/1999) 5-year predicted survival—hypothetical Cases 1, 2 and 3.

Pediatric heart transplant (1/1995 to 6/1999) 5-year predicted survival conditional on survival to 1 year—hypothetical Case 1.

Age distribution of pediatric lung recipients by year of transplant.

Age distribution by donor type for pediatric lung recipients (transplants: January 1996 to June 2004).

Diagnosis in pediatric lung recipients age 11 to 17 years.

Pediatric lung recipient maintenance immunosuppression at time of follow-up. Note: Different patients analyzed at Year 1 and Year 5 (follow-up: January 2001 and June 2004).

Pediatric lung recipient induction immunosuppression for follow-up between January 2001 and June 2004.

Pediatric lung transplant Kaplan-Meier survival by era (transplants: January 1988 to June 2003).

Pediatric lung transplant conditional Kaplan-Meier survival by age group (transplants: January 1990 to June 2003).

Pediatric lung transplant Kaplan-Meier survival by donor type for age 11 to 17 years (transplants: January 1990 to June 2003).

Pediatric lung transplant Kaplan-Meier survival by procedure type (transplants: January 1990 to June 2003).

Pediatric lung transplant Kaplan-Meier survival stratified by induction use (transplants: January 2001 to June 2004).

Freedom from bronchiolitis obliterans for pediatric lung recipients (follow-up: April 1994 to June 2004).

Freedom from bronchiolitis obliterans for pediatric lung recipients by induction use (transplants: April 1994 to June 2004).

Pediatric lung recipients’ functional status (follow-up: April 1994 to June 2004).